U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509047) titled 'Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children' on Dec. 31, 2025.
Brief Summary: This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant. The study will guide the future dosing schedule and formulation of CCV (with or without Aluminum phosphate adjuvant) expected to be needed in adults and children in cholera-endemic region.
Study Start Date: Jan. 13
Study Type: INTERVENTIONAL
Condition:
Cholera Vaccination
Intervention:
BIOLOGICAL: OS...